Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mn

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, UNLOXCYT, to a broader market. The acquisition enhances Sun Pharma's oncology portfolio and aims to provide a new treatment option for cSCC patients. Completion is expected by the second calendar quarter of 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Cx54qe
via IFTTT